Abstract:Background Prognosis of small (≤2 cm) invasive lung adenocarcinoma remains poor, and identification of high-risk individuals from the patients after complete surgical resection of lung adenocarcinoma has become an urgent problem. YBX1 has been reported to be able to predict prognosis in many cancers (except lung adenocarcinoma) that are independent of TNM (tumor, nodes, metastases) staging, especially small invasive lung adenocarcinoma. Therefore, we examined the significance of YBX1 expression on prognosis and recurrence in patients with small invasive lung adenocarcinoma. Material and methods A total of 75 patients with small invasive lung adenocarcinoma after complete resection were enrolled from January 2008 to December 2010. Immunohistochemical staining was used to detect the expression of YBX1, and receiver operating characteristic curve analysis was performed to precisely assess the overall expression of YBX1. Meanwhile, primary lesions were identified based on the International Association for the Study of Lung Cancer, the American Thoracic Society, and the European Respiratory Society’s classification of lung adenocarcinoma. The effect of different clinicopathological factors on patients’ survival was examined. Furthermore, Western blot analysis was used to show the expression of YBX1 in vitro. Results Sensitivity and specificity of YBX1 for detecting small invasive lung adenocarcinoma from normal surrounding tissue were 66.7% and 74.7% (area under the receiver operating characteristic curve =0.731; P<0.001), respectively. High YBX1 expression was detected in 31 (41.3%) patients, and in A549, H322, Hcc827, and H1299 lung adenocarcinoma cells but not in HLF cells. In addition to sex, age, tumor size, TNM staging, pleural invasion, and lymph node metastasis, the expression of YBX1 was associated with the International Association for the Study of Lung Cancer, the American Thoracic Society, and the European Respiratory Society pathological grade risk (P=0.026) and differentiation (P=0.009). The patients with low YBX1 expression lived longer than those with high expression (5-year overall survival: 52.3% vs 79.0%; P=0.039) and showed fewer recurrences (P=0.024). In multivariate analyses, high YBX1 expression (odds ratio =2.737; 95% confidence interval: 1.058–7.082; P=0.038) was shown as an independent risk factor of overall survival but not of disease-free survival (odds ratio =1.696; 95% confidence interval: 0.616–4.673; P=0.307). Conclusion YBX1 is an important predictor for the prognosis in patients with small invasive lung adenocarcinoma after complete resection.

Elevated nuclear YBX1 expression and the clinicopathological characteristics of patients with solid tumors: a meta-analysis.

High Expression of Y-box-binding Protein 1 Correlates with Poor Prognosis and Early Recurrence in Patients with Small Invasive Lung Adenocarcinoma

YBX1 as a prognostic biomarker and potential therapeutic target in hepatocellular carcinoma: A comprehensive investigation through bioinformatics analysis and in vitro study

Exploration of YBX1 role in the prognostic value and immune characteristics by single‐cell and bulk sequencing analysis for liver hepatocellular carcinoma

Comprehensive pan-cancer analysis of YBX family reveals YBX2 as a potential biomarker in liver cancer

In silico analysis of overall survival with YBX1 in male and female solid tumours

Prognostic value of ZEB-1 in solid tumors: a meta-analysis

High expression of HOXB7 is an unfavorable prognostic factor for solid malignancies A meta-analysis

Evaluation of Expression of UHRF1 and Its Prognostic and Clinicopathological Value in Human Malignancies: A Systematic Review and Meta-analysis

Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies

Clinicopathological Significance and Prognostic Values of Long Noncoding RNA BCYRN1 in Cancer Patients: A Meta-Analysis and Bioinformatics Analysis

Prognostic Value of High EZH2 Expression in Patients with Different Types of Cancer: a Systematic Review with Meta-Analysis

Effects of Y Box Binding Protein-1 in Progression and Prognosis of Cholangiocarcinoma.

YB1 Associates with Oncogenetic Roles and Poor Prognosis in Nasopharyngeal Carcinoma

MYC Overexpression with Its Prognostic and Clinicopathological Significance in Breast Cancer.

Ybx1 Regulates Tumor Growth Via Cdc25a Pathway in Human Lung Adenocarcinoma

Prognostic and clinicopathological value of BUB1B expression in patients with lung adenocarcinoma: a meta-analysis

Poor Prognosis And Satb1 Overexpression In Solid Tumors: A Meta-Analysis

YBX1 Enhances Metastasis and Stemness by Transcriptionally Regulating MUC1 in Lung Adenocarcinoma

Effect of Y-box binding protein 1 on tumor and its research

SP1 Expression and the Clinicopathological Features of Tumors: A Meta-Analysis and Bioinformatics Analysis.